Evidence map›Paper›PMID 40454906›Full record

ArticleInternational journal of cancer2025

Patient factors and modifications to intended chemotherapy for women with Stages I-IIIA breast cancer.

Jenna Bhimani, Peng Wang, Grace B Gallagher, Kelli O'Connell, Victoria Blinder, Rachael Burganowski, Isaac J Ergas, Jennifer J Griggs, Narre Heon, Tatjana Kolevska and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Response to Yu, Wang, and Ge.Journal of the National Cancer Institute · 2026
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Jenna BhimaniDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Peng WangDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0003-4303-6081
Grace B GallagherDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Kelli O'ConnellDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Victoria BlinderDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Rachael BurganowskiKaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, Washington, USA.
Isaac J ErgasDivision of Research, Kaiser Permanente Northern California, Pleasanton, California, USA.
Jennifer J GriggsDivision of Hematology/Oncology, Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Narre HeonDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Tatjana KolevskaDepartment of Oncology, Kaiser Permanente Medical Center, Vallejo, California, USA.
Yuriy KotsurovskyyDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Candyce H KroenkeDivision of Research, Kaiser Permanente Northern California, Pleasanton, California, USA.
Cecile A LaurentDivision of Research, Kaiser Permanente Northern California, Pleasanton, California, USA.
Raymond LiuDivision of Research, Kaiser Permanente Northern California, Pleasanton, California, USA.
Kanichi G NakataKaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, Washington, USA.
Sonia PersaudDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Janise M RohDivision of Research, Kaiser Permanente Northern California, Pleasanton, California, USA.
Sara TabatabaiDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Emily ValiceDivision of Research, Kaiser Permanente Northern California, Pleasanton, California, USA.
Elisa V BanderaCancer Epidemiology and Health Outcomes, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
Erin J Aiello BowlesKaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, Washington, USA.
Lawrence H KushiDivision of Research, Kaiser Permanente Northern California, Pleasanton, California, USA.
Elizabeth D KantorDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0002-9124-5323

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Risk-based Imaging Strategies to Improve Breast Cancer Surveillance OutcomesP01CA154292 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Diana L Miglioretti · 2011 to 2026
$52.9M
Infrastructure for Pathways, a Prospective Study of Breast Cancer SurvivorshipU01CA195565 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI AMBROSONE, CHRISTINE B., KUSHI, LAWRENCE H · 2016 to 2025
$18.8M
CRN4: Cancer Research Resources & Collaboration in Integrated Health Care SystemsU24CA171524 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI KUSHI, LAWRENCE H · 2012 to 2016
$16.0M
Obesity, chemotherapy dosing, and breast cancer outcomesR37CA222793 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI KANTOR, ELIZABETH DAVID · 2018 to 2024
$4.0M
Group Health Cancer Research Program Research Specialist AwardR50CA211115 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI BOWLES, ERIN JANELLE AIELLO · 2017 to 2021
$919k
Geoffrey Beene Cancer Research CenterNCI NIH HHS P01 CA154292NCI NIH HHS P01CA154292NCI NIH HHS P30 CA008748NCI NIH HHS P30CA008748NCI NIH HHS R37 CA222793NCI NIH HHS R37CA222793NCI NIH HHS R50 CA211115NCI NIH HHS R50CA211115NCI NIH HHS U01 CA195565NCI NIH HHS U01CA195565NCI NIH HHS U24 CA171524NCI NIH HHS U24CA171524
6 · The paper itself

Abstract

Modifications to intended chemotherapy regimens may be due to various reasons and may impact patient outcomes. Understanding which factors are associated with chemotherapy modifications can help inform treatment planning and improve cancer care. We examined the association between patient/tumor factors and modifications to intended chemotherapy in women with Stages I-IIIA breast cancer who were treated at Kaiser Permanente Northern California and Kaiser Permanente Washington from 2005 to 2019. Modifications were defined as any dose reductions in the first cycle or throughout chemotherapy, regimen change, treatment delay (single delay >14 days) or receiving fewer cycles of any drugs than expected. We used generalized linear models of the Poisson family with a log-link function to calculate prevalence ratios (PRatios). Of 9700 women receiving adjuvant chemotherapy, 34.6% had chemotherapy modifications. Selected results are shown: positive associations were observed with age (PRatio

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsAdolescentAdultAgedAged, 80 and overAge FactorsBody Mass IndexChemotherapy, AdjuvantFemaleHumansMiddle AgedNeoplasm StagingYoung Adultadjuvant chemotherapybreast cancerchemotherapy modificationpatient factors

Identifiers

PMID40454906
PMCPMC12335361

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.